Vortex Medical Inc: Endovascular Innovation
Finding endomechanical solutions to endovascular problems
Founded in 2008, Vortex Medical Inc. is a medical device company focused on the design, development, and commercialization of novel endomechanical devices for the endovascular market.
With the help of its Scientific Advisory Board (SAB), Vortex Medical strives to find innovative endomechanical solutions to common endomechanical problems. The SAB is made up of specialists in the field, most notably Dr. Ken Rosenfield a leader in the field of interventional cardiology and the section head for Vascular Medicine and Intervention at Massachusetts General Hospital. Dr. Rosenfield will chair the Vortex Medical Scientific Advisory Board.
The AngioVac® Cannula represents the first product offered by Vortex Medical with a clearance in 2009 for use as a venous drainage cannula. The AngioVac Circuit is the second cleared product with an indication for use during procedures requiring extracorporeal circulatory support.
This novel venous drainage cannula has a balloon actuated distal funnel tip that facilitates en bloc removal of undesirable intravascular material during the performance of extracorporeal circulation.
“We are focused on improving lives through innovation. We are currently pioneering unique endovascular solutions to common endovascular problems.”
— Mike Glennon (CEO, Vortex Medical)
Mike Glennon: CEO, Vortex Medical Inc.
Vortex Medical, CEO Mike Glennon, is a highly experienced executive in the medical device industry. Mike has extensive experience with new platform product introduction in the area’s of product design, development, supply chain solutions management, sales and marketing. Mike has worked for various medical device companies including Accellent, Medtronic, Guidant and Stryker Endoscopy.
Josh Philips: Director, Vortex Medical Inc.
Joshua Phillips is the Managing General Partner of Catalyst Health Ventures (CHV), an early stage healthcare and life science focused venture firm in the Boston area. Josh leads Catalyst’s investment activities in all areas and he represents CHV on the boards of Allegro Diagnostics Inc., Vortex Medical Inc., BioTrove Inc. (Chairman), HepreGen Corp., and Castel Inc. (Chairman) and previously lead CHV’s investment in Novazyme Pharmaceuticals (acquired by Genzyme).
Al Chin: Director, Vortex Medical Inc.
Al is one of the most successful medical device inventors of our time. He is responsible for over 168 issued patents covering 12 marketed products. There has been over $1billion in revenue to date from sales of his marketed products. Al was co-founder of Origin Medsystems, spent 20 years with Guidant Corporation and was most recently the Chief Innovation Officer at Maquet Cardiovascular.